Navigation Links
Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
Date:11/23/2007

PRINCETON, N.J., and PARIS, Nov. 23 /PRNewswire-FirstCall/ -- Bristol- Myers Squibb Company (NYSE: BMY) and Pierre Fabre Medicament reported today that they are terminating their license agreement for the development of vinflunine, a chemotherapy agent under investigation for the treatment of advanced or metastatic bladder cancer and other tumor types. Vinflunine was developed by Pierre Fabre Medicament and licensed to Bristol-Myers Squibb in 2004 for specific territories. Based on a review of the clinical development program and the decision not to file a new drug application for bladder cancer in the United States, coupled with an analysis of Bristol-Myers Squibb's Research & Development priorities, the companies have jointly decided that all rights licensed to Bristol-Myers Squibb for vinflunine will be returned to Pierre Fabre Medicament.

"In Europe, Pierre Fabre Medicament intend to continue discussions with regulatory authorities and plan to file for the registration of vinflunine for bladder cancer in the first quarter of 2008," said P. Hurteloup, General Manager of Pierre Fabre Medicament Oncology Division. "We also are considering a range of further development options, including pursuing the product on a worldwide basis for the treatment of a number of cancers."

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

Pierre Fabre Medicament is a French private group dedicated to consumers and patients from health to beauty.


'/>"/>
SOURCE Bristol-Myers Squibb Company; Pierre Fabre Medicament
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Bristol-Myers Squibb to Acquire Adnexus Therapeutics
3. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
4. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
5. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
6. CardioDynamics Provides 2007 Shareholder Meeting Update
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
9. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
10. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
11. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... have just published their findings on what they believe could be a new ... summary of the new research. Click here to read it now. ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
Breaking Biology News(10 mins):